Here are the Form 4 insider transactions from BlackRock Capital Allocation Term Trust (BCAT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAT filings page.
BlackRock Capital Allocation Term Trust Vice President Stephen Thomas Minar reported exercising 7,035 transferable subscription rights for 1,407 common shares, issued on October 27, 2026. The subscription price was $13.30 per share; holders could subscribe for one new common share for every five rights, while holders of fewer than five common shares on the September 25, 2026 record date could subscribe for one share. Minar's reported direct common-stock holdings after the transaction were 8,348 shares.
BlackRock Capital Allocation Term Trust director Robert W. Fairbairn exercised 9,200 transferable subscription rights on October 27, 2026, and acquired 1,840 common shares. His reported direct common-share holdings after the transaction were 11,044 shares. The Trust’s rights offering set a subscription price of $13.30 per share and generally provided one new share for every five Rights; holders with fewer than five common shares on the September 25, 2026 record date could subscribe for one share.
BlackRock Capital Allocation Term Trust portfolio manager Richard M. Rieder reported an open-market sale of 35,734 shares of Common Stock on 2026-07-13 at an average price of $15.9601 per share. Following this transaction, he directly owns 272,353 shares of the trust.
BlackRock Capital Allocation Term Trust portfolio manager Sarah Croughan Thompson reported insider transactions involving common stock and phantom shares. On January 30, 2026, 693.8508 phantom shares were converted into 693.8508 common shares at an exercise price of $0.00 and then sold at $14.70 per share, leaving zero common shares directly held.
After these moves, Thompson continues to hold 1,387.7016 phantom shares, which are cash-settled instruments economically equivalent to common stock. According to the disclosure, these phantom shares were granted on January 31, 2025 and vest in three equal annual installments, becoming payable in cash as they vest.
BlackRock Capital Allocation Term Trust portfolio manager Koesterich Russell Jared reported multiple transactions dated January 30, 2026. He exercised 5,554.0398 shares of common stock and then disposed of 5,554.0398 shares at $14.7 per share, leaving 33,000 common shares held directly.
He also settled phantom share awards tied to prior grants. One block of 3,414.0154 phantom shares and another of 2,140.0245 phantom shares, each economically equivalent to common stock, were moved, leaving 6,828.0307 and 2,140.0245 phantom shares, respectively. Phantom shares are payable in cash as they vest in three annual installments from the January 31, 2024 and January 31, 2025 grant dates.
BlackRock Capital Allocation Term Trust portfolio manager Randy William Berkowitz reported an insider stock sale. On January 30, 2026, he acquired 3,680.3862 shares of common stock at a transaction price of $0.00 per share and then sold the same 3,680.3862 shares at $14.70 per share, leaving no common shares directly owned after the transactions.
Separately, he reported activity in phantom shares, which are stated to be the economic equivalent of common stock and payable in cash on vesting. Transactions covered 712.1738 and 2,968.2123 phantom shares tied to prior grants from January 31, 2024 and January 31, 2025.